Samlyn Capital’s Satsuma Pharmaceuticals STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-2,929,195
Closed -$17.6M – 118
2022
Q3
$17.6M Sell
2,929,195
-15,060
-0.5% -$85.4K 0.33% 63
2022
Q2
$12.2M Buy
2,944,255
+149,046
+5% +$526K 0.24% 68
2022
Q1
$10.6M Buy
2,795,209
+1,025,355
+58% +$4.62M 0.15% 87
2021
Q4
$7.96M Buy
1,769,854
+53,787
+3% +$273K 0.11% 94
2021
Q3
$8M Buy
1,716,067
+132,178
+8% +$700K 0.11% 104
2021
Q2
$11.2M Buy
1,583,889
+351,495
+29% +$1.9M 0.16% 80
2021
Q1
$7.28M Buy
+1,232,394
New +$7.47M 0.1% 102

Other funds holding STSA

Samlyn Capital's STSA Position: Q4 2022 in Review

Samlyn Capital sold out of Satsuma Pharmaceuticals (STSA) in Q4 2022, closing a stake of 2,929,195 shares — an estimated $17.6M sold.

Samlyn Capital first reported a position in STSA in Q1 2021 and held it in 7 quarters. The position peaked at $17.6M in Q3 2022. 32 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

  • Samlyn Capital reported no remaining Satsuma Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Samlyn Capital sold 2,929,195 Satsuma Pharmaceuticals shares in Q4 2022, an estimated $17.6M.
  • Samlyn Capital first reported a position in Satsuma Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Samlyn Capital's Satsuma Pharmaceuticals position peaked at $17.6M in Q3 2022.
  • 32 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals as of Q4 2022.

Based on Samlyn Capital's 13F filing for Q4 2022, filed 14 Feb 2023.